Drugs / 68Ga-FAPI-46
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT06922825 | Jan 2027 → Apr 2032 | cancer | Eben Rosenthal | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 0 | NCT05365802 | Nov 2021 → Dec 2026 expected | drug or radiation exposure-related interstitial lung disease, hypersensitivity pneumonitis, idiopathic interstitial pneumonia, pneumoconiosis +2 | University of California, Los Angeles | Recruiting | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT05172310 | Jun 2021 → Jun 2024 overdue | bile duct neoplasm, gastric neoplasm, malignant epithelial tumor of ovary, pancreatic neoplasm | Karolinska University Hospital | Recruiting | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT07478523 | Apr 2026 → Mar 2028 expected | cholangiocarcinoma, pancreatic adenocarcinoma | University Hospital, Bordeaux | Recruiting | No outcome recorded |
| Phase 2 | NCT06659705 | Dec 2025 → Aug 2029 expected | pancreatic ductal adenocarcinoma | Institut Curie | Recruiting | No outcome recorded |
| Phase 2 | NCT05898854 | Feb 2024 → Dec 2025 | gastric cancer, gastroesophageal cancer | Aalborg University Hospital | Completed | No outcome recorded |
| Phase 2 | NCT05903807 | Nov 2023 → May 2026 | ovarian cancer | Aalborg University Hospital | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT05262855 | May 2022 → Mar 2025 | pancreatic ductal adenocarcinoma | SOFIE | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06957782 | Sep 2025 → Mar 2027 expected | peritoneal carcinomatosis | Erasmus Medical Center | Not yet recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 68Ga-FAPI-46 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06922825 ↗ |
| Action | Inhibit | “Gallium-68 labelled fibroblast activation protein inhibitor (FAPI)” NCT05903807 ↗ |
| Modality | Diagnostic / imaging agent | “for imaging studies with Positron Emission Tomography (PET).” NCT05172310 ↗ |
| Route | Intravenous | “will be administered intravenously 60 minutes prior to whole-body PET image acquisition.” NCT05172310 ↗ |
| Target | FAP | “The FAP inhibitor, FAPI, gets selectively enriched in tissues where its target protein is expressed” NCT05172310 ↗ |